Sana Biotechnology (SANA) Competitors $1.65 +0.05 (+3.13%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SANA vs. EVO, ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, MESO, TVTX, and NTLAShould you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Sana Biotechnology vs. Evotec Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Travere Therapeutics Intellia Therapeutics Sana Biotechnology (NASDAQ:SANA) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment. Do analysts rate SANA or EVO? Sana Biotechnology currently has a consensus price target of $13.50, indicating a potential upside of 718.18%. Evotec has a consensus price target of $5.93, indicating a potential upside of 32.74%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more volatility & risk, SANA or EVO? Sana Biotechnology has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Is SANA or EVO more profitable? Evotec's return on equity of 0.00% beat Sana Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Sana BiotechnologyN/A -84.22% -44.97% Evotec N/A N/A N/A Does the MarketBeat Community believe in SANA or EVO? Sana Biotechnology received 12 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 58.06% of users gave Sana Biotechnology an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformSana BiotechnologyOutperform Votes1858.06% Underperform Votes1341.94% EvotecOutperform Votes654.55% Underperform Votes545.45% Which has higher earnings & valuation, SANA or EVO? Evotec has higher revenue and earnings than Sana Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSana BiotechnologyN/AN/A-$283.26M-$1.40-1.18Evotec$777.05M2.04-$90.82MN/AN/A Does the media favor SANA or EVO? In the previous week, Evotec had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 3 mentions for Evotec and 0 mentions for Sana Biotechnology. Evotec's average media sentiment score of 1.57 beat Sana Biotechnology's score of 0.00 indicating that Evotec is being referred to more favorably in the news media. Company Overall Sentiment Sana Biotechnology Neutral Evotec Very Positive Do institutionals and insiders believe in SANA or EVO? 88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 31.1% of Sana Biotechnology shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummarySana Biotechnology and Evotec tied by winning 7 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Sana Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SANA vs. The Competition Export to ExcelMetricSana BiotechnologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$368.39M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-1.1846.7391.3417.19Price / SalesN/A411.851,117.70116.80Price / CashN/A182.1042.6437.86Price / Book1.133.894.794.78Net Income-$283.26M-$42.21M$120.07M$225.60M7 Day Performance-12.70%-2.14%-1.90%-1.23%1 Month Performance-29.79%4.21%11.45%3.37%1 Year Performance-59.85%18.40%30.63%16.58% Sana Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SANASana Biotechnology2.0915 of 5 stars$1.65+3.1%$13.50+718.2%-59.8%$368.39MN/A-1.18328EVOEvotec2.3873 of 5 stars$4.68+4.2%$5.93+26.8%-60.5%$1.66B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.8607 of 5 stars$13.31+4.9%$15.50+16.5%+478.8%$1.56B$138.71M-7.58150Options VolumeNRIXNurix Therapeutics2.5081 of 5 stars$21.13+4.2%$30.35+43.6%+101.7%$1.50B$56.42M-6.97300News CoverageRCUSArcus Biosciences2.6571 of 5 stars$16.26+1.1%$34.00+109.1%-9.3%$1.49B$117M-5.11500News CoverageKNSAKiniksa Pharmaceuticals2.5294 of 5 stars$20.50+1.5%$36.60+78.5%+15.4%$1.48B$384.10M-147.36220Positive NewsIMCRImmunocore2.4978 of 5 stars$29.12+0.7%$65.64+125.4%-51.4%$1.46B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.6461 of 5 stars$9.04+4.0%$16.71+84.9%+116.8%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.0474 of 5 stars$12.16+3.4%$11.50-5.4%+590.1%$1.39B$5.90M0.0080Analyst ForecastOptions VolumeNews CoverageGap DownTVTXTravere Therapeutics2.7815 of 5 stars$17.73+2.4%$22.62+27.6%+106.0%$1.38B$145.24M-3.81460Positive NewsNTLAIntellia Therapeutics4.1284 of 5 stars$13.50+4.7%$54.94+306.9%-58.9%$1.37B$36.28M-2.37600 Related Companies and Tools Related Companies EVO Competitors ARQT Competitors NRIX Competitors RCUS Competitors KNSA Competitors IMCR Competitors OCUL Competitors MESO Competitors TVTX Competitors NTLA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SANA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
